★★★

Boditech Med

Boditech Med 2026 Q1 Sales +9.6%, Treasury Stock 6.2% Canceled


  • **Treasury stock cancellation**: 1,438,250 shares (6.2% of total listed shares) canceled on March 6, 2026. Future buyback and cancellation plan at least 5% of annual net profit.
  • **Consolidated sales growth**: Q1 sales KRW 42.8B (+9.6% YoY), operating profit KRW 6.8B (-15.8%), net profit KRW 9.5B (+30.9%).
  • **Financial stability**: Total assets KRW 296.0B, debt ratio 16.04%, equity ratio 86.2%. Cash & equivalents KRW 39.7B (+103% vs year-end).
  • **R&D investment**: R&D expenses KRW 5.5B (12.8% of sales), continuous development of new products and platforms.
  • **Operating profit decline**: SG&A expenses increased due to R&D, regulatory, and marketing hires. Net profit surged due to financial gains.

KOSDAQ Filing Information


  • Filing: Quarterly Report (2026.03)
  • Company: Boditech Med (206640)
  • Submission: Boditech Med Inc.
  • Receipt: 05-15-2026